Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
KNKinnate Biopharma Inc. logo

Kinnate Biopharma Inc. (KNTE)

NASDAQ Global Select · Currency in USD
$2.65 ▼ -0.01 (-0.38%)
At close: Apr 2, 4:00 PM ET. Market closed.

Summary

Previous Close
$2.66
Open
$2.65
Day's Range
$2.64 – $2.68
52 Week Range
$1.04 – $7.19
Volume
2,121,570
Avg. Volume
417,575
Market Cap
$124.99M
Beta (5Y Monthly)
1.34
PE Ratio (TTM)
--
EPS (TTM)
-$2.42
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$30.00

Profile: Kinnate Biopharma Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
84
CEO
Nima Farzan

Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3.

Earnings

DateEst.Actual
May 9, 2024-$0.34-$0.73Miss
Mar 27, 2024-$0.42-$0.36Beat
Nov 9, 2023-$0.69-$0.65Beat
Aug 8, 2023-$0.76-$0.68Beat
May 11, 2023-$0.73-$0.73Beat
Mar 15, 2023-$0.70-$0.72Miss

Analyst view

Consensus price target
$30.00 ▲ +1,032.1%
Range $30.00 – $30.00
Rating: Hold
Buy 33% · Hold 67% · Sell 0%

Get free alerts on KNTE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.